SCHEMBL461664

SCHEMBL461664

CCCCCN1CC(=O)NC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.45
ALOX5 P09917 2/20 0.42
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
GBA1 P04062 1/20 0.40
PTGS1 P23219 3/20 0.38
PTGS2 P35354 3/20 0.38
MGLL Q99685 3/20 0.38
FAAH O00519 3/20 0.38
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
DUT P33316 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PLA2G2A P14555 2/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162839 0.98 ALOX5 (0.45) CRBNALOX5CYP4F2CYP4A11GBA1
SCHEMBL3628533 0.98 ALOX5 (0.45) CRBNALOX5CYP4F2CYP4A11GBA1
SCHEMBL20376257 0.98 ALOX5 (0.45) CRBNALOX5CYP4F2CYP4A11GBA1
SCHEMBL6228568 0.98 ALOX5 (0.45) CRBNALOX5CYP4F2CYP4A11GBA1
SCHEMBL6233217 0.98 ALOX5 (0.45) CRBNALOX5CYP4F2CYP4A11GBA1
SCHEMBL20441211 0.98 ALOX5 (0.45) CRBNALOX5CYP4F2CYP4A11GBA1
SCHEMBL8716131 0.98 ALOX5 (0.45) CRBNALOX5CYP4F2CYP4A11GBA1
SCHEMBL6233785 0.98 ALOX5 (0.45) CRBNALOX5CYP4F2CYP4A11GBA1
SCHEMBL194067 0.94 CRBN (0.46) CRBNALOX5CYP4F2CYP4A11GBA1
SCHEMBL4190795 0.87 CRBN (0.46) CRBNALOX5CYP4F2CYP4A11PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419422-B1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA SAS (FR) 2014-10-15 EP claimed
US-8624037-B2 Imidazolidine-2,4-dione derivatives and use thereof as a medicament IPSEN PHARMA S.A.S. (FR) 2014-01-07 US claimed
US-20120095068-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2012-04-19 US claimed
EP-1778827-A1 STABLE NONAQUEOUS BLEACHING DETERGENT COMPOSITION DISPERSION JohnsonDiversey, Inc., Renee J. Rymarz (US) 2007-05-02 EP claimed
WO-2006014223-A1 STABLE NONAQUEOUS BLEACHING DETERGENT COMPOSITION DISPERSION JOHNSONDIVERSEY, INC. (US) 2006-02-09 WO claimed
CN-1454042-A Method for producing printing circuit board SHEPLEY CO (US) 2003-11-05 CN claimed
CN-1039283-C Use of Porphyrins FMC CORP (US) 1998-07-29 CN claimed
US-5407808-A Treating tumor with inhibitor of protoporphyrinogen conversion to heme FMC CORPORATION (US) 1995-04-18 US claimed
US-5298502-A Exposure to light in presence of oxidase inhibitor FMC CORPORATION (US) 1994-03-29 US claimed
EP-0447491-B1 PROTOPORPHYRINOGEN INHIBITORS AND THEIR USE IN COMPOSITIONS FOR DETECTING AND TREATING TUMOURS FMC CORP (US) 1993-08-11 EP claimed
WO-2023235480-A1 ARYL HYDANTOIN COMPOUNDS AND METHODS OF USE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2023-12-07 WO disclosed
WO-2023235480-A1 ARYL HYDANTOIN COMPOUNDS AND METHODS OF USE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2023-12-07 WO disclosed
US-20230135524-A1 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-05-04 US disclosed
CN-113801064-A Method for constructing phenylhydantoin by [3+2] cycloaddition reaction 甘肃省化工研究院有限责任公司 2021-12-17 CN disclosed
CN-109796437-B Hydantoin and thiohydantoin compounds with AR and HDAC dual inhibition effects and application 上海健康医学院 2021-08-24 CN disclosed
EP-0011693-A1 N-trifluoromethane-sulfonylaminophenyl-substituted N-heterocycles, their preparation, compositions containing them and their use in regulating plant growth CIBA-GEIGY AG (CH) 1980-06-11 EP disclosed
EP-0003861-A1 Detergent bleach composition and process for removing stains from cotton fabrics THE PROCTER & GAMBLE COMPANY (US) 1979-09-05 EP disclosed
US-4003841-A Coated stabilized bleach activators, process and washing compositions HENKEL & CIE G.M.B.H. (DT) 1977-01-18 US disclosed
US-3975280-A Storage-stable, readily-soluble detergent additives, coating compositions and process HENKEL & CIE G.M.B.H. (DT) 1976-08-17 US disclosed
US-3780056-A ACYL HYDANTOIN PHOSPHOROTHIOATES SINGHAL G 1973-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135524-A1 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE CYP21A2, AR, NR5A1 CRBN 1178/4885ALOX5 3471/4885CYP4F2 236/4885
US-20120095068-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT MKI67, CCNI, CCNA1 CRBN 1729/4885ALOX5 3022/4885CYP4F2 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.